Trial Profile

Efficacy of ibrutinib as a front-line therapy in patients with chronic lymphocytic leukemia: A retrospective cohort study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use

Most Recent Events

04 Dec 2018 Results (n=128 treated with Ibrutinib at a single academic center from 2011-2017) assessing Ibrutinib-associated musculoskeletal toxicities presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
26 Dec 2017 New trial record
12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com